-- In 2012, consolidated revenue totalled DKK 8,555 million, matching a growth
     rate of just over 6%, with acquisitions and changes in foreign exchange
     rates being the growth drivers, whereas organic growth was modest.
  -- The Group's three business activities Hearing Devices, Diagnostic
     Instruments and Personal Communication achieved growth rates in revenue of
     5%, 23% and 8%, respectively.
  -- In 2012, the Group generated an operating profit (EBIT) of DKK 1,653
     million against DKK 1,709 million in 2011. The profit margin was 19.3%.
  -- Consolidated cash flow from operating activities amounted to DKK 1,272
     million, which is slightly above the 2011 level, if we adjust for the
     payment of DKK 118 million in connection with the closing of the ETG patent
     infringement case.
  -- Oticon's new high-end hearing aid, Oticon Alta, which was successfully
     launched in January 2013 and is based on the also brand new Inium platform,
     sets new standards for natural sound and speech intelligibility. Oticon
     Alta has been well received and is now available on all main markets.
  -- In 2013, we expect organic revenue growth in our wholesale of hearing aids
     to exceed market growth rates by 3-5 percentage points in local currencies
     and thus expect to continue to increase our market share. In 2013,
     corporate operating profit (EBIT) is expected to exceed the level realised
     in 2012.